|1.||Bagheri, Bita: 1 article (01/2002)|
|2.||Scher, Richard K: 1 article (01/2002)|
|3.||Rubin, Adam I: 1 article (01/2002)|
01/01/1997 - "The in vitro antifungal activity of the new hydroxypyridone antimycotic rilopirox has been evaluated against 29 separate clinical isolates of Malassezia (M.) furfur obtained from patients with pityriasis versicolor, seborrhoeic dermatitis or dandruff. "
01/01/2002 - "Rilopirox is a hydrophobic, topical agent with potential application in mucosal candida infections, tinea versicolor and seborrheic dermatitis. "
|2.||HIV Infections (HIV Infection)
04/01/1999 - "The in vitro antifungal activity of the new hydroxypyridone antimycotic rilopirox has been evaluated against 38 fluconazole-susceptible and -resistant clinical isolates of Candida albicans together with other Candida species isolated from patients with human immunodeficiency virus (HIV) infection and oropharyngeal candidosis. "
04/01/1999 - "In vitro activity of rilopirox against fluconazole-susceptible and fluconazole-resistant Candida isolates from patients with HIV infection."